In a rare breakthrough into a developed market, the South Korean pharmaceutical regulatory agency approved a Cuban medicine, Cuba’s Center for Genetic Engineering and Biotechnology (CIGB) announced in a tweet.
No further context was immediately available.
According to the CIGB tweet, South Korea’s Ministry of Food and Drug Safety approved Heberprot-P, a biotech product that treats diabetic foot ulcers, for use with Korean patients.
Recombinant human epidermal growth factor-based Heberprot, which was first approved in Cuba in 2006, has been registered in Vietnam, Malaysia, Turkey, Argentina, Colombia, Kuwait, Ukraine, and Russia, among others. An agreement with a U.S. company in 2016 to bring Heberprot-P to clinical testing in the United States seems to have faded … read more